RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer

Advanced Non-small Cell Lung Cancer Clinical Trial

Official title:

A Phase 1 Trial of RO5126766 (CH5126766) in Patients With Advanced KRAS-Mutant Lung Adenocarcinomas

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03681483
• Other study ID #: 18-285
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: October 31, 2018
• Est. completion date: September 2024

Study information

• Verified date: October 2023
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to test the safety of RO5126766 at different doses to find out what effects, if any, it has on people with advanced lung cancer who have previously received treatment with a PD-1 or PD-L1 inhibitor.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 15
• Est. completion date: September 2024
• Est. primary completion date: September 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically or cytologically proven diagnosis of advanced NSCLC
• Documented presence of KRAS mutation
• Prior treatment with a PD-1/L1 inhibitor. Patients who were deemed not eligible for therapy with a PD-1/L1 inhibitor by their treating physician will also be eligible in the dose expansion phase.
• Prior treatment with chemotherapy
• Able to take oral medications
• Measurable and/or evaluable disease (RECIST 1.1) indicator lesion not previously irradiated
• Karnofsky performance status (KPS) = 70% (ECOG of 0 or 1 also acceptable)
• Age= 18 years old
• Hematological and biochemical indices within the ranges shown below Hematological and biochemical indices within the ranges shown below (These measurements must be performed within two weeks [Day 14 to Day 1] before the patient is entered into the trial).
• AST, ALT = 2.5 x ULN - Total bilirubin = 1.5 x ULN -Albumin=2.5g/dL
• Creatinine < 1.5 x ULN OR calculated creatinine clearance =50mL/min
• Absolute neutrophil count (ANC) = 1,200 cells/mm3
• Hemoglobin =9.0 g/dL
• Platelets =100,000/mm^3.
• A negative serum pregnancy test obtained within two weeks prior to the administration of the study drug in all women of child bearing potential

Exclusion Criteria:

• Patients with symptomatic brain metastasis requiring escalating doses of steroids
• Patients with grade 2 or greater diarrhea prior to study initiation despite maximal medical management
• History of any bowel disease including abdominal fistula, gastro-intestinal perforation
• History of acute pancreatitis within 1 year of study entry or history of chronic pancreatitis
• History of or ongoing alcohol abuse that, in the opinion of the treating physician, would compromise compliance or impart excess risks associated with study participation.
• Pregnant or lactating women
• Any type of systemic therapy (chemotherapy or experimental drugs) within 3 weeks of starting treatment on protocol (within 6 weeks for for nitrosoureas and mitomycin C)
• Radiotherapy within 2 weeks of starting treatment on protocol
• Prior treatment with MEK, RAF, or ERK inhibitor(s)
• Significant uncontrolled or active cardiovascular disease, specifically including, but

not restricted to:

• History of clinically significant (as determined by the treating physician) atrial arrhythmia
• Any ventricular arrhythmia
• History of congenital long QT syndrome.
• Abnormal QTc (= 450 msec in males and = 470 msec in females)
• Ejection fraction = 50% as assessed by echocardiogram
• Concurrent congestive heart failure
• Prior history of class III/ IV heart failure (New York Heart Association [NYHA]
• Myocardial infarction within the last 6 months
• Unstable angina or severe obstructive pulmonary disease
• Patients with baseline risk factors for central serous retinopathy or retinal vein occlusion such as evidence of new optic disc cupping, evidence of new visual field defects, and intraocular pressure >21 mmHg Uncontrolled hypertension (Diastolic blood pressure > 100 mmHg; Systolic blood pressure > 150 mmHg).
• History of central serous retinopathy or retinal vein occlusion
• History of prior malignancy within 2 years that requires/ed treatment. Patients who are considered NED from a malignancy may be considered on a case by case basis.
• Known active hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infections
• Patients exposed to CYP3A4 inhibitors within 7 days prior to the first dose and CYP3A4 inducers 7 days prior to the first dose. RO5126766 (CH5126766) is metabolised mainly by CYP3A4 therefore concomitant administration of strong inhibitors and inducers of cytochrome p450 3A4 enzymes is forbidden during study treatment (for a complete list please see Appendix A).
• Any other condition that, in the opinion of the investigator, may compromise the safety, compliance of the patient, or would preclude the patient from successful completion of the study

Related Conditions & MeSH terms

• Advanced Non-small Cell Lung Cancer
• Lung Neoplasms

Intervention

Drug:
• RO5126766
RO5126766 (CH5126766) is given 4mg twice weekly (Day 1 and Day 4 of each week) and should be taken by mouth on an empty stomach, either one hour before or two hours after a meal.

Locations

Country	Name	City	State
United States	Lehigh Valley Health Network	Allentown	Pennsylvania
United States	Miami Cancer Institute	Miami	Florida
United States	Memorial Sloan Kettering Cancer Center	New York	New York

Sponsors (3)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center	Chugai Pharma USA, Dana-Farber Cancer Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The maximum tolerated dose (MTD)	will be defined as the highest dose level at which = 1 of 6 patients experienced a DLT.The NCI Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE) will be used to grade toxicities during the trial. DLTs are defined as any toxicity occurring during the first cycle of treatment (i.e. 4 weeks), excluding toxicites clearly related to disease progression or disease-related processes.	1 year
Primary	overall response rate (dose expansion)	by RECIST 1.1	1 year

External Links

•   Memorial Sloan Kettering Cancer Center